Peptides DB
Research-centric peptide and protocol reference hub

Bofanglutide record · updated 6h ago

Metabolic & appetiteGrade A · human clinicalResearch use only
All 15 studiesJump to the evidenceCompare
What is Bofanglutide used for?

Research peptide discovered via AI researcher. research peptide

Primarily researched for · Metabolic & appetite

Development stage

where Bofanglutide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 11 registered trials. It describes the research record, not a recommendation.

Identity
NameBofanglutide
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMetabolic
Research levelModerate Research
Discovered byThe Librarian · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 7, 2026. How this works →
Research stats
Total studies15
Human / animal / cellular3 / 0 / 5
Highest trial phasePhase 4
Years covered2023–2026
Latest study16d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

15 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Bridging Biosynthesis and Bioavailability: Integrated Strategies for Tailoring Soybean Isoflavone Profiles.
TakeawayThis review outlines strategies for optimizing soybean isoflavone profiles, emphasizing genetic and processing interventions, but lacks new experimental data.
review2026Full text read0.80
Spatiotemporal dynamics of the host-tumor metabolic interface: Implications for precision nutritional oncology.
TakeawayPrecision nutritional oncology could potentially enhance cancer treatment by targeting metabolic interactions, but further research is needed to validate these concepts in clinical settings.
review2026Full text read0.80
One Health implementation for rabies elimination in India by 2030: Progress, governance, challenges, and policy alignment.
TakeawayAchieving rabies elimination in India by 2030 requires addressing governance and surveillance gaps and improving access to prophylaxis.
review2026Full text read0.70
A Ready-to-Use Recombinant Yeast Two-Hybrid Assay for Thyroxine Detection.
FindingEC50 values ranged from 350 nM to 550 nM for thyroxine.
In vitro2026Full text read0.70
Fe(III)-(II) Mineral Transformation and Associated Organic Matter Stabilization Processes in a Tidal Marsh Soil.
FindingNot reported in abstract.
In vitro2026Full text read0.70
Global, regional, and national burden of HIV/AIDS, 1990-2023, with the estimated burden attributable to intimate partner violence and forecasted impacts of funding cuts through 2030: results from the Global Burden of Disease Study 2023.
Finding2.06 million new HIV infections globally in 2023 (1.88-2.29 million).
review2026Full text read0.90
Assessing the Prognostic Value of Serial Seattle Angina Questionnaire Scores in Chronic Coronary Disease.
FindingEach 5-point increase in the current SAQ-SS was associated with a 7% lower risk of the primary endpoint (hazard ratio, 0.93 [95% CI, 0.90-0.96]).
Human2023Full text read0.80
Flexible solar cells based on foldable silicon wafers with blunted edges.
TakeawayNot reported in abstract.
—2023Title only0.10
NK2R control of energy expenditure and feeding to treat metabolic diseases.
TakeawayNot reported in abstract.
—2024Title only0.10
Air-permeable hydrogels through viscoelastic phase separation of aerogels.
FindingOxygen permeability of 185 barrer with 70 vol% water.
review2026Partial text0.40
Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants.
FindingRelative bioavailability was 0.56% for 30/60 mg and 1.31% for 90 mg.
Human2026Full text read0.80
Miniaturized Droplet-Based Adaptation of the Ames Test for High-Throughput Mutagenicity Assessment.
FindingCytotoxic suppression at ≥ 8 μg/mL.
In vitro2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Bofanglutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Bofanglutide is discussed should be drawn from it.